MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.Read More
Recent Press Releases
03/04/19MyoKardia Announces Positive Six-Month Safety and Efficacy Data from PIONEER-OLE Study of Mavacamten for the Treatment of Symptomatic, Obstructive HCM
NASDAQ GS | MYOK (Common Stock)
$54.31 - 1.51
10/26/184:00 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.
There are currently no events scheduled.